Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trialMonika Graeser,Sherko Kuemmel,Oleg Gluz,Friedrich Feuerhake,Valery Volk, Daniel Ulbrich-Gebauer,Claudia Biehl,Mattea Reinisch,Athina Kostara,Iris Scheffen,Kerstin Luedtke-Heckenkamp,Andreas Hartkopf,Felix Hilpert,Angela Kentsch,Carsten Ziske,Reinhard Depenbusch,Michael Braun,Jens-Uwe Blohmer,Christine Zu Eulenburg,Matthias Christgen,Ronald Kates,Stephan Bartels, Hans-Heinrich Kreipe,Enrico Pelz,Peter Schmid,Nadia HarbeckCANCER RESEARCH（2023）引用 0|浏览21暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
